BioXcel Therapeutics, Inc. Increase (Decrease) in Interest Payable, Net
BioXcel Therapeutics, Inc. (BTAI) reported Increase (Decrease) in Interest Payable, Net of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-27.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInInterestPayableNet · last filed 2026-03-27
- BioXcel Therapeutics, Inc. increase (decrease) in interest payable, net for the quarter ending 2025-12-31 was $0.00.
- BioXcel Therapeutics, Inc. increase (decrease) in interest payable, net for the quarter ending 2025-09-30 was $0.00.
- BioXcel Therapeutics, Inc. increase (decrease) in interest payable, net for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- BioXcel Therapeutics, Inc. increase (decrease) in interest payable, net for the quarter ending 2024-09-30 was -$79.00K.
- BioXcel Therapeutics, Inc. increase (decrease) in interest payable, net for fiscal 2025 was $0.00.
- BioXcel Therapeutics, Inc. increase (decrease) in interest payable, net for fiscal 2024 was -$736.00K, a 129.48% decline from fiscal 2023.
- BioXcel Therapeutics, Inc. increase (decrease) in interest payable, net for fiscal 2023 was $2.50M, a 34.36% decline from fiscal 2022.
- BioXcel Therapeutics, Inc. increase (decrease) in interest payable, net for fiscal 2022 was $3.80M.
| Period end | Increase (Decrease) in Interest Payable, Net 3 month | Increase (Decrease) in Interest Payable, Net 6 month | Increase (Decrease) in Interest Payable, Net 9 month | Increase (Decrease) in Interest Payable, Net 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $0.00 derived: sum of 2 quarters · filed 2026-03-27 | $0.00 10-K · filed 2026-03-27 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $0.00 10-Q · filed 2025-11-12 | ||
| 2025-06-30 | $0.00 10-Q · filed 2025-08-12 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$79.00K derived: sum of 2 quarters · filed 2026-03-27 | -$117.00K derived: sum of 3 quarters · filed 2026-03-27 | -$736.00K 10-K · filed 2026-03-27 |
| 2024-09-30 | -$79.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$117.00K derived: sum of 2 quarters · filed 2025-11-12 | -$736.00K 10-Q · filed 2025-11-12 | $608.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$38.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$657.00K 10-Q · filed 2025-08-12 | $687.00K derived: sum of 3 quarters · filed 2025-08-12 | -$394.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$619.00K 10-Q · filed 2025-05-12 | $725.00K derived: sum of 2 quarters · filed 2025-05-12 | -$356.00K derived: sum of 3 quarters · filed 2025-05-12 | $685.00K derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $1.34M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $263.00K derived: sum of 2 quarters · filed 2025-03-28 | $1.30M derived: sum of 3 quarters · filed 2025-03-28 | $2.50M 10-K · filed 2025-03-28 |
| 2023-09-30 | -$1.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$40.00K derived: sum of 2 quarters · filed 2024-11-14 | $1.15M 10-Q · filed 2024-11-14 | $2.06M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $1.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $2.23M 10-Q · filed 2024-08-06 | $3.14M derived: sum of 3 quarters · filed 2024-08-06 | |
| 2023-03-31 | $1.19M 10-Q · filed 2024-05-09 | $2.10M derived: sum of 2 quarters · filed 2024-05-09 | ||
| 2022-12-31 | $908.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-22 | $3.80M 10-K · filed 2024-03-22 | ||
| 2022-09-30 | $2.90M 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |